Impetigo Bulosa

01Pathophysiology

Bullous impetigo is a localized, toxin-mediated infection of the superficial epidermis caused exclusively by Staphylococcus aureus. Unlike non-bullous impetigo, which can be caused by either S. aureus or Group A Streptococcus, the bullous form is always staphylococcal. This distinction is high-yield.

The pathogenic strains belong to phage group II (most commonly type 71) and produce exfoliative toxins A and B (ETA and ETB). These toxins function as serine proteases that selectively cleave desmoglein 1 (Dsg1), a desmosomal cadherin responsible for cell-to-cell adhesion in the granular layer of the epidermis. The cleavage of Dsg1 causes loss of keratinocyte adhesion (acantholysis) at the subcorneal or intragranular level, resulting in the formation of a superficial intraepidermal blister.

This mechanism directly explains the clinical presentation. Because the split occurs very superficially, the resulting bullae have thin, fragile roofs that rupture easily. After rupture, the base appears shiny and eroded, a finding described as a "varnished" or "lacquered" appearance surrounded by a collarette of residual scale from the collapsed blister roof. The Nikolsky sign is negative because the toxin acts locally at the site of bacterial colonization, not systemically. The surrounding normal skin has intact desmoglein and will not shear with lateral pressure.

This same exfoliative toxin mechanism underlies Staphylococcal Scalded Skin Syndrome (SSSS), but in SSSS, the toxin is produced at a distant site and reaches the skin hematogenously, causing widespread, generalized epidermal cleavage with a positive Nikolsky sign. Bullous impetigo, by contrast, represents the localized end of the exfoliative toxin disease spectrum. Understanding this spectrum is the key to distinguishing these two conditions on an exam.

The reason neonates and young children are disproportionately affected relates to two factors. First, they lack anti-exfoliative toxin antibodies that older children and adults develop over time. Second, their immature renal clearance means they are less efficient at clearing circulating toxin, increasing vulnerability if the disease begins to extend beyond localized infection.

02Classification and Clinical Manifestation

Bullous impetigo falls within the broader classification of impetigo. The table below contrasts its two primary forms, which is a commonly tested comparison.

A critical pearl from this table: only non-bullous impetigo caused by nephritogenic strains of GAS carries a risk of post-streptococcal glomerulonephritis (PSGN). Bullous impetigo, being purely staphylococcal, never leads to PSGN. However, neither form of impetigo causes acute rheumatic fever, because impetigo-associated GAS strains are non-rheumatogenic. This is a frequently tested distinction.

03Diagnostic Workup

In the vast majority of clinical scenarios, bullous impetigo is a clinical diagnosis based on the characteristic morphology of flaccid bullae or post-rupture collarette erosions in a neonate or young child. The exam vignette will describe the lesion appearance, and you are expected to recognize it and initiate treatment without further testing.

When the question asks for the best initial test to confirm the organism, the answer is Gram stain and culture of fluid aspirated from an intact bulla. This is the ideal specimen because the blister fluid in bullous impetigo contains viable bacteria (unlike SSSS, where the bullae are sterile because the toxin arrives hematogenously). Gram stain will show gram-positive cocci in clusters, and culture will confirm S. aureus and provide antibiotic sensitivities.

If the question stem presents a diagnostically ambiguous case (for example, a child with blistering that could represent bullous impetigo, SSSS, pemphigus, or bullous pemphigoid), the most accurate test is a skin biopsy. Histopathology in bullous impetigo shows a subcorneal or intragranular split (cleavage within or just below the granular layer) with neutrophils and acantholytic keratinocytes. Direct immunofluorescence will be negative, which distinguishes it from autoimmune blistering diseases like pemphigus vulgaris (which shows intercellular IgG/"fishnet" pattern) or bullous pemphigoid (which shows linear IgG/C3 at the basement membrane zone).

A high-yield distinction for the workup: if you culture the blister fluid in bullous impetigo, it grows S. aureus. If you culture the blister fluid in SSSS, it is sterile. The reason is that in SSSS, the blistering is caused by toxin that has spread through the bloodstream from a remote focus (nasopharynx, umbilicus, or wound), not from local bacterial presence in the skin.

04Management and Treatment

Acute management begins with gentle wound care. Parents should be instructed to wash affected areas with mild soap and water and remove crusts with warm compresses before applying topical antibiotics. This improves drug penetration and reduces bacterial burden.

For localized disease with only a few lesions, topical mupirocin 2% applied three times daily for 5 to 7 days is the first-line treatment. Mupirocin works by inhibiting bacterial isoleucyl-tRNA synthetase, which is a unique mechanism that avoids cross-resistance with systemic antibiotics. Retapamulin is an acceptable alternative but is less commonly tested. Topical fusidic acid is used in some regions but is not a standard answer in most licensing exam contexts.

When the disease is extensive (defined as numerous lesions, rapid spread, or involvement of multiple body areas), oral systemic antibiotics are required. The first-line choice is a beta-lactamase-resistant penicillin or first-generation cephalosporin: cephalexin or dicloxacillin. These cover methicillin-sensitive S. aureus (MSSA), which remains the most common cause. If the vignette provides risk factors for MRSA (recent hospitalization, prior MRSA infection, failure of initial therapy, high community MRSA prevalence), switch to TMP-SMX or clindamycin.

For neonates or any patient with signs of systemic toxicity (fever, irritability, poor feeding, widespread involvement), the next best step is hospitalization with IV antibiotics. The standard regimen is IV nafcillin or oxacillin for MSSA coverage. If MRSA is suspected or the patient is critically ill, IV vancomycin is used with dosing adjusted to trough levels (target 10 to 15 mcg/mL in standard infections).

An important contraindication: do not use topical therapy alone in neonates, even if the disease appears localized. Neonates are at higher risk of rapid progression to SSSS or bacteremia due to their immature immune system and poor renal toxin clearance. Any bullous impetigo in a neonate should prompt a lower threshold for systemic antibiotics and close monitoring.

Long-term management includes decolonization strategies for recurrent cases. This involves intranasal mupirocin twice daily for 5 days and chlorhexidine body washes to reduce S. aureus carriage. Household contacts may also require decolonization if recurrence is a problem.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with bullous impetigo is confusing it with SSSS. Both are caused by S. aureus exfoliative toxins and both present with superficial blistering in young children. The discriminator the exam tests over and over is this: bullous impetigo is localized with a negative Nikolsky sign and culture-positive blister fluid, while SSSS is generalized with a positive Nikolsky sign and sterile blister fluid. If the vignette describes a well-appearing child with a few blisters on the trunk, think bullous impetigo. If it describes a toxic-appearing neonate with diffuse erythema, widespread skin peeling, and pain with gentle touch, think SSSS.

A second common error is assuming bullous impetigo can lead to post-streptococcal glomerulonephritis. Students sometimes apply the PSGN association from impetigo broadly without recognizing that this complication only follows infection with nephritogenic GAS strains. Bullous impetigo is caused exclusively by S. aureus and carries no PSGN risk. Similarly, neither form of impetigo leads to rheumatic fever, because skin strains of GAS are non-rheumatogenic.

The third pitfall involves treatment selection. When the vignette describes localized disease, the answer is topical mupirocin, not oral antibiotics. Students often over-treat. Conversely, when the patient is a neonate or has extensive or worsening disease, the answer shifts to systemic antibiotics, and topical therapy alone is insufficient. Recognizing the threshold for escalation is the core competency being tested.

Finally, remember that the Nikolsky sign is a frequent distractor across blistering diseases. It is positive in pemphigus vulgaris and SSSS (both involving disruption of intercellular adhesion broadly) but negative in bullous impetigo and bullous pemphigoid. If a question stem mentions Nikolsky sign, it is steering you toward one of these diagnoses, and your job is to match the sign with the correct clinical context.